Atlas Trials

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Clinical trial NCT02456350 · UNKNOWN

Trial details

NCT number
NCT02456350
Sponsor
Shenzhen Second People's Hospital
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Chronic Lymphocytic LeukemiaAcute Lymphocytic LeukemiaLymphoma
Start date
2015-04-01
Primary completion
2019-12-01
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.